Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Vertex Pharmaceuticals (NQ:VRTX)

439.01 +0.36 (+0.08%)
Streaming Delayed Price Updated: 9:56 AM EDT, May 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
Wondering what's happening in today's S&P500 pre-market session?
Discover the top S&P500 movers in Tuesday's pre-market session and stay informed about market dynamics. 
Via Chartmill
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
This Vertex Pharmaceuticals Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Tuesday
Via Benzinga
Vertex Pharma Stock’s Retail Buzz Intensifies As 2025 Revenue View Lift Fails To Offset Q1 Miss
The company’s Q1 revenue missed expectations, but the company raised its 2025 revenue guidance, reflecting optimism about growth drivers like cystic fibrosis treatments and its expanding pipeline. 
Via Stocktwits
Topics World Trade
Exposures Tariff
Earnings Scheduled For May 5, 2025
Via Benzinga
Earnings Outlook For Vertex Pharmaceuticals
Via Benzinga
Monday's after hours session: top gainers and losers in the S&P500 index
Let's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top S&P500 gainers and losers in today's after hours session. 
Via Chartmill
Vertex Pharmaceuticals Stock Falls On Q1 Earnings, Revenue Miss — Company Raises Low End Of FY25 Revenue Guidance
Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period. 
Via Benzinga
Vertex Pharmaceuticals (NASDAQ:VRTX) Reports Sales Below Analyst Estimates In Q1 Earnings
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) missed Wall Street’s revenue expectations in Q1 CY2025 as sales rose 3% year on year to $2.77 billion. The company’s full-year revenue guidance of... 
Via StockStory
Vertex Reports First Quarter 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
Vertex Has Lost Some Sizzle Into Q1 Earnings - Can Alyftrek, Journavx Reignite The Momentum?
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports Q1 earnings with $4.32 EPS and $2.85B revenue. Stock up 25.48% in past year, charts show bullish trend. 
Via Benzinga
Stocks Pause Gains As Treasury Yields Rise: What's Driving Markets Monday?
Wall Street kicked off the week with a cautious tone, as major stock indices hovered near the flatline by midday in New York. Investors digested fresh signs of inflationary pressure in the services... 
Via Benzinga
Vertex Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Via Benzinga
Stock Market Selloff: 4 No-Brainer Stocks to Buy Right Now
Now may be a smart time to buy small stakes in these fundamentally robust companies. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Economy
3 No-Brainer Stocks to Buy in May
Via The Motley Fool
5 Growth Stocks to Buy in May and Go Away
Via The Motley Fool
Topics Artificial Intelligence Government World Trade
Exposures Artificial Intelligence Political Tariff
Earnings To Watch: Vertex Pharmaceuticals (VRTX) Reports Q1 Results Tomorrow
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be announcing earnings results tomorrow afternoon. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
Exposures Artificial Intelligence
S&P Global, Berkshire Hathaway, CME Group And A Health Care Stock: CNBC's 'Final Trades'
Via Benzinga
Topics Stocks
Exposures US Equities
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Technical Breakout Potential
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Shows Strong Technical Breakout Potential 
Via Chartmill
These 3 Funds Offer Sky-High Yields of 15% or More and Trade at a Discount
Via The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
Via Benzinga
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising... 
Via Talk Markets
Topics ETFs Stocks / Equities
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
Via The Motley Fool
Topics Artificial Intelligence Energy
Exposures Artificial Intelligence Fossil Fuels
Why Vertex Pharmaceuticals Was Such a Healthy Stock on Tuesday
Via The Motley Fool
3 Relatively Safe Healthcare Growth Stocks You Can Buy and Hold
Via The Motley Fool
Topics Government
Exposures Political
Expert Outlook: Vertex Pharmaceuticals Through The Eyes Of 18 Analysts
Via Benzinga
Fed Chairman Jerome Powell Warns Trump's Tariffs Could Cause Stagflation: 3 Stocks to Buy and Hold if He's Right
Via The Motley Fool
Topics Economy Government World Trade
Exposures Economy Interest Rates Political
Vertex Has A Lot Riding On Alyftrek, Journavx — And Investors Are Watching Closely
Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and potential upside surprises. 
Via Benzinga
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next
Via The Motley Fool
Topics Government World Trade
Exposures Political Tariff
Peering Into Vertex Pharmaceuticals's Recent Short Interest
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.